Enzo Biochem Inc.

Enzo Biochem disclosed in an 8-K (Item 8.01) that it entered agreements effective August 8, 2024 with the Attorneys General of New York, New Jersey and Connecticut resolving inquiries related to a ransomware attack the Company experienced in April 2023. The Company agreed to pay $4.5 million, divided among the three AGs, and to implement cybersecurity enhancements and an Information Security Program. The Company neither admits nor denies the investigative findings.

Home - Enzo Biochem

Enzo Biochem, Inc. experienced a ransomware attack on April 6, 2023, impacting IT systems. On April 11, 2023, the company became aware that names, test information, and Social Security numbers were accessed and, in some instances, exfiltrated. Approximately 2,470,000 individuals had clinical test information accessed, with SSNs of ~600,000 potentially involved. The company disconnected systems, engaged third-party experts, and notified law enforcement. Investigation is ongoing.

Enzo Biochem, Inc. reported a ransomware attack on April 6, 2023, impacting IT systems. On April 11, 2023, the company discovered that certain data was extracted. The company disconnected systems, engaged third-party experts, and activated its disaster recovery plan. The investigation is ongoing. No specific count of affected individuals or detailed data types were disclosed, though the company serves patients and partners.

enzo.com